{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~46 mi. (Obninsk, Russia, +383 more cities)
facility
Federal State Institution Medical Radiology Research Center
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~46 mi. (Obninsk, Russia, +153 more cities)
facility
A.Tsyb Medical Research Radiological Center of the Ministry of Health of the Russian Federation
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~46 mi. (Obninsk, Russia, +93 more cities)
facility
National Medical Research Radiology Centre ( Site 0869)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
city
~46 mi. (Obninsk, Russia, +190 more cities)
facility
MRRC n.a. A.F. Tsyb - branch of FSBI "NMRC of Radiology" Minzdrav Russia, +2 more facilities
biomarker
ATM Loss, +27 more biomarkers
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~51 mi. (Kaluga, Russia, +201 more cities)
facility
Kaluga Regional Clinical Hospital /ID# 221211
drug
azacitidine, +1 more drug
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
city
~55 mi. (Tula, Russia, +142 more cities)
facility
Tula Regional Clinical Hospital
biomarker
del(11)(q10), +27 more biomarkers
drug
imetelstat, +1 more drug
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~68 mi. (Podolsk, Russia, +89 more cities)
facility
Podolsk Regional Clinical Hospital ( Site 1907)
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~98 mi. (Moscow, Russia, +192 more cities)
facility
Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~98 mi. (Moscow, Russia, +144 more cities)
facility
Moscow Oncological Clinical Dispensary #1 ( Site 2619), +1 more facility
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~98 mi. (Moscow, Russia, +176 more cities)
facility
FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 2634)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types